Turning complexity
into clarity.
Axiom Point develops proprietary algorithms that read the hidden structure of cancer biology — and translate it into precise, actionable intelligence for drug discovery.
An independent computational oncology research company. Years of focused work across cancer biology and data analysis have produced something we hold closely: algorithms built to find what others miss.
Synthetic Lethal Targets
We identify synthetic lethal gene-pair targets — vulnerabilities that only emerge in combination — opening therapeutic windows that single-target screening cannot reveal.
Resistance Architecture
We predict the architecture of resistance before it forms — mapping how and where a tumour is likely to escape, so therapies can be designed to close those routes.
Drug Sequencing Intelligence
We generate drug sequencing intelligence for combination therapy — the order and timing that turn a set of agents into a coherent, durable strategy.
We do not publish our methodology. We deliver results.
The intelligence is the asset. We keep our methods proprietary and let the outcomes speak — inside our partners' programmes, not in the literature.
Bring this intelligence into your drug-discovery programmes.
We are seeking partnerships with pharmaceutical and biotechnology companies ready to apply Axiom Point's intelligence to their pipelines. If that's you, we should talk.
Start a conversation →